Cite
Genome-Scale CRISPR screen identifies LAPTM5 driving lenvatinib resistance in hepatocellular carcinoma.
MLA
Pan, Jiaomeng, et al. “Genome-Scale CRISPR Screen Identifies LAPTM5 Driving Lenvatinib Resistance in Hepatocellular Carcinoma.” Autophagy, vol. 19, no. 4, Apr. 2023, pp. 1184–98. EBSCOhost, https://doi.org/10.1080/15548627.2022.2117893.
APA
Pan, J., Zhang, M., Dong, L., Ji, S., Zhang, J., Zhang, S., Lin, Y., Wang, X., Ding, Z., Qiu, S., Gao, D., Zhou, J., Fan, J., & Gao, Q. (2023). Genome-Scale CRISPR screen identifies LAPTM5 driving lenvatinib resistance in hepatocellular carcinoma. Autophagy, 19(4), 1184–1198. https://doi.org/10.1080/15548627.2022.2117893
Chicago
Pan, Jiaomeng, Mao Zhang, Liangqing Dong, Shuyi Ji, Juan Zhang, Shu Zhang, Youpei Lin, et al. 2023. “Genome-Scale CRISPR Screen Identifies LAPTM5 Driving Lenvatinib Resistance in Hepatocellular Carcinoma.” Autophagy 19 (4): 1184–98. doi:10.1080/15548627.2022.2117893.